89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas
Cirrhotic liver
89bio's pegozafermin shows fibrosis reduction in small subgroup of cirrhotic NASH patients • Source: Shutterstock

More from Clinical Trials

More from R&D